谷物衍生的蛋白质和对血糖水平的影响
Kazumi Ninomiya1, Yusuke Yamaguchi2, Nao Matsubara2
1Division of Molecular Science, Graduate School of Science and Technology, Gunma University, Kiryu, Gunma 376-8515, Japan.
Journal of agricultural and food chemistry
|May 17, 2025
概括
谷物蛋白及其可以通过抑制粉消化和增强胰岛素分泌来帮助控制血糖. 这些发现支持它们在功能性食品中用于糖尿病管理中的使用.
科学领域:
- 营养科学 营养科学
- 生物化学 生物化学
- 食品科学 食品科学 食品科学
背景情况:
- 血糖水平升高是糖尿病并发症的关键因素.
- 谷物蛋白及其具有调节葡萄糖的潜力.
研究的目的:
- 探索谷物蛋白和调节血糖的机制.
- 突出其在功能性食品中的潜在应用,用于糖尿病管理.
主要方法:
- 在谷物和豆类中对蛋白质性α-氨酶抑制剂 (α-AIs) 的分析.
- 研究可消化蛋白与葡萄糖的相互作用.
- 对对葡萄糖载体和DPP-IV抑制的影响的评估.
主要成果:
- α-AIs 抑制了粉的分解,减少了餐后葡萄糖峰值.
- 难以消化的蛋白质像纤维一样,吸附和分泌葡萄糖.
- 可以抑制葡萄糖的吸收,并通过DPP-IV抑制促进胰岛素的分泌.
结论:
- 谷物蛋白和为血糖调节提供了多种途径.
- 这些成分对开发功能性食品来帮助糖尿病管理具有显著的前景.
相关概念视频
Hormones Regulating Blood Glucose
2.9K
Insulin is released by beta cells of the pancreas when blood glucose levels are high. It facilitates glucose absorption and utilization in insulin-dependent cells with insulin receptors on their plasma membranes. Insulin promotes glucose uptake by increasing the number of glucose transport proteins in the cell membrane, allowing glucose to enter the cell. As a result, glucose utilization and ATP production are enhanced.
In addition to accelerating glucose uptake and utilization, insulin has...
In addition to accelerating glucose uptake and utilization, insulin has...
2.9K
Glucose Homeostasis: Regulation of Blood Glucose
1.3K
Carbohydrates consumed through foods are converted into glucose, a crucial energy source for the body. In the prandial state, high blood glucose levels stimulate the secretion of insulin from the pancreas. Insulin inhibits hepatic glucose production and stimulates glucose uptake and metabolism by muscle and adipose tissue. The excess glucose is converted into glycogen and stored in the liver and muscles.
During fasting, when blood glucose levels are low, the pancreas secretes glucagon. it...
During fasting, when blood glucose levels are low, the pancreas secretes glucagon. it...
1.3K
Hypoglycemia and Glucagon
143
Without prolonged fasting, healthy individuals maintain blood glucose levels above 3.5 mM due to a well-adapted neuroendocrine counterregulatory system that effectively prevents acute hypoglycemia, a potentially life-threatening condition. The primary clinical scenarios for hypoglycemia encompass diabetes treatment, inappropriate production of endogenous insulin or insulin-like substances by tumors, and the use of glucose-lowering agents in non-diabetic individuals. Notably, hypoglycemia in the...
143
Overview of Carbohydrate Metabolism
619
Carbohydrate metabolism is a fundamental biochemical process that ensures a constant supply of energy to living cells. The most important carbohydrate is glucose, which can be broken down via glycolysis to enter into the Krebs cycle and eventually lead to the production of ATP through oxidative phosphorylation.
Glucose transport into cells is facilitated by a family of transport proteins called GLUT (Glucose Transporters). GLUT4 is the primary glucose transporter for insulin-stimulated glucose...
Glucose transport into cells is facilitated by a family of transport proteins called GLUT (Glucose Transporters). GLUT4 is the primary glucose transporter for insulin-stimulated glucose...
619
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
134
α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...
Acarbose and miglitol are...
134
Glucagon-like Receptor Agonists
277
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
277


